Answers are grounded in this paper and cite their sources.
BACKGROUND: HER2-positive breast cancer is a distinct subtype associated with less favorable outcomes without targeted therapy. Dual HER2 blockade with pertuzumab and trastuzumab has shown improved efficacy compared to single-agent approaches, but results across studies remain variable. This meta-analysis aims to evaluate the overall efficacy and safety of pertuzumab-based regimens. METHODS: A systematic search of PubMed, Scopus, Web of Science, and the Cochrane Library was conducted to identify relevant RCTs. The quality of trials was assessed using the ROB-2 tool, and the certainty of the evidence was assessed using the GRADE tool. Data were synthesized using R. RESULTS: This study included 8 RCTs with 8367 patients. Pertuzumab-based regimens were associated with improved overall survival. In the locally advanced or metastatic setting, a pronounced benefit was observed (HR = 0.71, 95% CI 0.65-0.77). However, in the neoadjuvant or adjuvant setting, the pooled hazard ratio (HR = 0.81, 95% CI 0.22-3.04), which was not significant. Progression-free survival (HR 0.74; 95% CI 0.67-0.83) was improved compared with the control group. In terms of safety, there was no significant difference in the incidence of any adverse events (risk ratio (RR) = 1.01; 95% CI 0.99-1.02) or grade ≥ 3 adverse events (RR 0.99; 95% CI 0.86-1.13) between the experimental and control groups. CONCLUSION: Pertuzumab-based dual HER2 blockade is associated with significant improvements in overall survival and progression-free survival in patients with metastatic HER2-positive breast cancer. Importantly, these survival benefits are not accompanied by a significant increase in overall or severe adverse events, supporting its favorable efficacy-safety profile across clinical settings.
No takes yet. Share an insight, caveat, or question.
Maeda et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: